Unicycive Therapeutics (UNCY) News Today $0.50 -0.03 (-5.66%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Unicycive presents on development progress of oxylanthanum carbonateOctober 28, 2024 | markets.businessinsider.comUnicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024October 28, 2024 | globenewswire.comRubius Therapeutics Inc Com (OTC:RUBY) Stock Quotes, Forecast and News SummaryOctober 20, 2024 | benzinga.comUnicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024October 16, 2024 | globenewswire.comUnicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024October 14, 2024 | globenewswire.comUnicycive Therapeutics: A Buy Rating with a $2.50 Price Target Amid Clinical and Regulatory AdvancesOctober 10, 2024 | markets.businessinsider.comUnicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy VolunteersOctober 9, 2024 | globenewswire.comUnicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024September 24, 2024 | globenewswire.comUnicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024September 16, 2024 | globenewswire.comBuy Rating Maintained for Unicycive Therapeutics Amidst OLC NDA Submission and Strong Financial OutlookSeptember 7, 2024 | markets.businessinsider.comUnicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | globenewswire.comUnicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on DialysisSeptember 3, 2024 | globenewswire.comUnicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024August 26, 2024 | globenewswire.comCompanies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In GrowthAugust 21, 2024 | finance.yahoo.comUnicycive Therapeutics, Inc.: Unicycive Announces Second Quarter 2024 Financial Results and Provides Business UpdateAugust 15, 2024 | finanznachrichten.deIndia's SpiceJet reports drop in Q1 profit on fewer flightsAugust 15, 2024 | uk.finance.yahoo.comUNCY Stock Earnings: Unicycive Therapeutics Beats EPS for Q2 2024August 14, 2024 | investorplace.comUnicycive Announces Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | globenewswire.comUNCY Unicycive Therapeutics, Inc.July 20, 2024 | seekingalpha.comUnicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)July 17, 2024 | globenewswire.comUnicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual ConferenceJuly 11, 2024 | globenewswire.comUnicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)July 10, 2024 | globenewswire.comUnicycive Therapeutics Joins Russell Microcap® IndexJuly 1, 2024 | globenewswire.comBuy Rating Affirmed on Unicycive Therapeutics Amid Promising Kidney Treatment AdvancesMay 29, 2024 | markets.businessinsider.comUnicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association CongressMay 28, 2024 | globenewswire.comUnicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor ConferenceMay 23, 2024 | globenewswire.comUnicycive Therapeutics, Inc.: Unicycive Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 15, 2024 | finanznachrichten.deUnicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical MeetingMay 15, 2024 | globenewswire.comUNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q1 2024May 14, 2024 | investorplace.comUnicycive Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 13, 2024 | globenewswire.com3 Top Penny Stocks to Buy for Explosive Returns: April EditionMay 9, 2024 | finance.yahoo.comThese 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper SandlerApril 29, 2024 | finance.yahoo.comBuy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial PositioningApril 12, 2024 | markets.businessinsider.comUnicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceApril 10, 2024 | globenewswire.comUnicycive Therapeutics: A Strong Buy on OLC’s Potential to Revolutionize Hyperphosphatemia Treatment in CKDApril 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial FootingApril 2, 2024 | markets.businessinsider.comUNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023March 28, 2024 | investorplace.comUnicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business UpdateMarch 28, 2024 | finance.yahoo.comUnicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business UpdateMarch 28, 2024 | globenewswire.comUnicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association CongressMarch 25, 2024 | globenewswire.comUnicycive reports progress in kidney injury treatment trialMarch 16, 2024 | investing.comBuy Rating on Unicycive Therapeutics Amidst Promising UNI-494 Drug Candidate ProspectsMarch 14, 2024 | markets.businessinsider.comUnicycive Announces $50 Million Private PlacementMarch 14, 2024 | globenewswire.comUnicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT ConferenceMarch 13, 2024 | globenewswire.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 64.3% in FebruaryUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) was the recipient of a large drop in short interest in February. As of February 29th, there was short interest totalling 35,000 shares, a drop of 64.3% from the February 14th total of 98,000 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average trading volume of 311,300 shares, the days-to-cover ratio is presently 0.1 days.March 12, 2024 | marketbeat.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)March 9, 2024 | finanznachrichten.deUnicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)March 7, 2024 | globenewswire.comBuy Rating Affirmed for Unicycive Therapeutics Amidst Promising UNI-494 Developments and FDA Orphan Drug DesignationMarch 6, 2024 | markets.businessinsider.comUnicycive Therapeutics (NASDAQ:UNCY) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $4.50 price target on shares of Unicycive Therapeutics in a research report on Tuesday.March 5, 2024 | marketbeat.comUnicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant PatientsMarch 4, 2024 | globenewswire.com Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now. Click here to see it because it’s a SHOCKER… UNCY Media Mentions By Week UNCY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UNCY News Sentiment▼0.280.41▲Average Medical News Sentiment UNCY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UNCY Articles This Week▼21▲UNCY Articles Average Week Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Atossa Therapeutics News Upexi News Sagimet Biosciences News Acumen Pharmaceuticals News Caribou Biosciences News Adaptimmune Therapeutics News Lifecore Biomedical News Corbus Pharmaceuticals News Actuate Therapeutics News Immutep News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UNCY) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
